Market open
Rocket Pharmaceuticals/$RCKT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rocket Pharmaceuticals
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Ticker
$RCKT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
299
ISIN
US77313F1066
Website
RCKT Metrics
BasicAdvanced
$652M
-
-$2.61
1.02
-
Price and volume
Market cap
$652M
Beta
1.02
52-week high
$26.98
52-week low
$4.55
Average daily volume
3.6M
Financial strength
Current ratio
9.19
Quick ratio
9.01
Long term debt to equity
5.454
Total debt to equity
6.151
Interest coverage (TTM)
-143.20%
Management effectiveness
Return on assets (TTM)
-34.80%
Return on equity (TTM)
-60.45%
Valuation
Price to book
1.57
Price to tangible book (TTM)
1.86
Price to free cash flow (TTM)
-2.815
Growth
Earnings per share change (TTM)
-8.44%
3-year earnings per share growth (CAGR)
-0.99%
What the Analysts think about RCKT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Rocket Pharmaceuticals stock.
RCKT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RCKT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RCKT News
AllArticlesVideos
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy
Business Wire·6 days ago
Rocket Pharma Out Of Orbit, But Ready For Relaunch
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Rocket Pharmaceuticals stock?
Rocket Pharmaceuticals (RCKT) has a market cap of $652M as of May 15, 2025.
What is the P/E ratio for Rocket Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rocket Pharmaceuticals (RCKT) stock is 0 as of May 15, 2025.
Does Rocket Pharmaceuticals stock pay dividends?
No, Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Rocket Pharmaceuticals dividend payment date?
Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders.
What is the beta indicator for Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.